Exciva

Exciva GmbH is a clinical-stage biopharmaceutical company focused on providing innovative therapies to address symptoms in Alzheimer's patients. Its lead candidate (Deraphan®) combines two compounds, demonstrating both safety profiles and effective activity in patients with behavioral conditions. The product has the potential to treat behavioral and psychological symptoms in Alzheimer's disease patients.